A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
Cherry Creek Medical Center
Highlands Ranch Hospital
University of Colorado Hospital
Study ID
Protocol Number: 20-2697
More information available at ClinicalTrials.gov: NCT03776071
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers